A Phase 3 interventional study of HOE901-U300 (new formulation of insulin glargine) and Lantus (insulin glargine) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 217 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-24.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment of the 175 interventional ones that give a count, is one of 5 that started in 2012, is one of 60 in phase 3, and was the 100th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 878 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 19th largest by enrollment of the 178 interventional ones that give a count, is one of 10 that started in 2012, is one of 80 in phase 3, and was the 112th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus
Secondary Objectives:
To compare a new formulation of insulin glargine and Lantus in terms of:
The maximum study duration was up to approximately 54 weeks per participant, consisting of:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HOE901-U300 (new formulation of insulin glargine)
Drug: Lantus (insulin glargine)
HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Also known as: Lantus
Change in HbA1c From Baseline to Month 6 Endpoint
Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Baseline, Month 6
Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6
Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \[mg/dL\]). Only nocturnal hypoglycemia occurring before initiation of rescue therapy were considered in the analysis. Week 9 and Month 6 value correspond to the observed value at Week 9 and Month 6 visit respectively.
Time frame: Week 9 Up to Month 6
Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Except for baseline value average of preinjection SMPG was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Baseline, Month 6
Variability of Preinjection SMPG at Month 6 Endpoint
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Month 6
Percentage of Participants With HbA1c <7% at Month 6
Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
Time frame: Month 6
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Baseline, Month 6
Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6
Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
Time frame: Month 6
Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6
Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 8-point SMPG profiles measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
Time frame: Baseline, Month 6
Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint
Change in 24-hour average of 8-point SMPG profile. 8-point SMPG was assessed at: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 24-hour average 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Baseline, Month 6
Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint
Variability is assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 5 measurements of the 8-point profiles. Only variability of 24-hour 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Baseline, Month 6
Change in Daily Basal Insulin Dose From Baseline to Month 6
Only insulin dose measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
Time frame: Baseline, Month 6
Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. Only DTSQ total score measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
Time frame: Baseline, Month 6
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
Time frame: Up to 12 months
A total of 1396 participants were screened, of whom 518 participants were screen failure and 878 participants were randomized.
| Milestone | HOE901-U300 | Lantus (Insulin Glargine) |
|---|---|---|
| Started | 439 | 439 |
| Treated | 435 | 438 |
| Modified intent-to-treat population | 432 | 430 |
| Completed | 337 | 314 |
| Not completed | 102 | 125 |
| Withdrew: Randomized but not treated | 4 | 1 |
| Withdrew: Adverse event | 10 | 8 |
| Withdrew: Lack of efficacy | 2 | 5 |
| Withdrew: Protocol violation | 11 | 12 |
| Withdrew: Received rescue therapy | 14 | 22 |
| Withdrew: Personal reason | 34 | 45 |
| Withdrew: Lost to follow-up | 11 | 18 |
| Withdrew: Selection criterion/protocol violation | 9 | 9 |
| Withdrew: Site closure/site withdrawal | 1 | 4 |
| Withdrew: Perceived lack of efficacy | 3 | 1 |
| Withdrew: Non serious hypoglycemia | 2 | 0 |
| Withdrew: No more need of insulin | 1 | 0 |
Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| percentage of hemoglobin | HOE901-U300 | Lantus |
|---|---|---|
| Change in HbA1c From Baseline to Month 6 Endpoint | -1.42 ± 0.047 | -1.46 ± 0.048 |
Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \[mg/dL\]). Only nocturnal hypoglycemia occurring before initiation of rescue therapy were considered in the analysis. Week 9 and Month 6 value correspond to the observed value at Week 9 and Month 6 visit respectively.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 | 15.5 | 17.4 |
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Except for baseline value average of preinjection SMPG was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint | -2.16 ± 0.162 | -2.33 ± 0.156 |
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| percentage of mean | HOE901-U300 | Lantus |
|---|---|---|
| Variability of Preinjection SMPG at Month 6 Endpoint | 18.70 ± 0.502 | 18.33 ± 0.521 |
Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With HbA1c <7% at Month 6 | 43.1 | 42.1 |
Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint | -3.41 ± 0.103 | -3.80 ± 0.105 |
Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6 | 26.2 | 29.5 |
Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 8-point SMPG profiles measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| 03:00 at Night Plasma Glucose (n=281,277) | -2.63 ± 3.24 | -3.01 ± 3.75 |
| Pre-Breakfast Plasma Glucose (n=292,286) | -3.28 ± 2.72 | -3.72 ± 2.96 |
| 2 Hours After Breakfast Plasma Glucose (n=278,278) | -3.69 ± 3.65 | -4.08 ± 4.03 |
| Pre-Lunch Plasma Glucose (n=289,281) | -2.58 ± 3.39 | -3.39 ± 3.76 |
| 2 Hours After Lunch Plasma Glucose (n=280,269) | -2.19 ± 3.88 | -3.13 ± 3.77 |
| Pre-Dinner Plasma Glucose (n=291,285) | -2.57 ± 3.49 | -2.43 ± 3.79 |
| 2 Hours After Dinner Plasma Glucose (n=282,269) | -2.36 ± 3.89 | -2.33 ± 4.03 |
| Bedtime Plasma Glucose (n=249,249) | -2.19 ± 3.75 | -2.26 ± 3.66 |
Change in 24-hour average of 8-point SMPG profile. 8-point SMPG was assessed at: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 24-hour average 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint | -2.72 ± 0.088 | -2.90 ± 0.089 |
Variability is assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 5 measurements of the 8-point profiles. Only variability of 24-hour 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| percentage of mean | HOE901-U300 | Lantus |
|---|---|---|
| Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint | 1.53 ± 0.643 | 1.41 ± 0.647 |
Only insulin dose measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.
| U/kg | HOE901-U300 | Lantus |
|---|---|---|
| Change in Daily Basal Insulin Dose From Baseline to Month 6 | 0.43 ± 0.29 | 0.34 ± 0.24 |
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. Only DTSQ total score measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.
| units on a scale | HOE901-U300 | Lantus |
|---|---|---|
| Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint | 4.89 ± 0.246 | 5.12 ± 0.251 |
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Any Hypoglycemia Event: All Hypoglycemia | 58.9 | 63.2 |
| Severe Hypoglycemia: All Hypoglycemia | 1.4 | 2.1 |
| Documented Symptomatic: All Hypoglycemia | 39.1 | 44.1 |
| Asymptomatic: All Hypoglycemia | 41.6 | 46.8 |
| Probable Symptomatic: All Hypoglycemia | 3.2 | 3.0 |
| Relative: All Hypoglycemia | 10.6 | 11.6 |
| Severe and/or Confirmed: All Hypoglycemia | 56.3 | 61.2 |
| Any Hypoglycemia Event: Nocturnal Hypoglycemia | 27.6 | 30.1 |
| Severe Hypoglycemia: Nocturnal Hypoglycemia | 0.0 | 0.7 |
| Documented Symptomatic: Nocturnal Hypoglycemia | 18.6 | 20.8 |
| Asymptomatic: Nocturnal Hypoglycemia | 13.3 | 16.0 |
| Probable Symptomatic: Nocturnal Hypoglycemia | 0.7 | 0.0 |
| Relative: Nocturnal Hypoglycemia | 4.4 | 3.2 |
| Severe and/or Confirmed: Nocturnal Hypoglycemia | 25.3 | 29.5 |
Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901-U300 | — | 35/435 (8%) | 115/435 (26.4%) |
| Lantus | — | 39/438 (8.9%) | 107/438 (24.4%) |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| Abdominal painGastrointestinal disorders | 0/435 | 3/438 |
| Atrial fibrillationCardiac disorders | 2/435 | 1/438 |
| Coronary artery diseaseCardiac disorders | 2/435 | 0/438 |
| Non-cardiac chest painGeneral disorders | 2/435 | 0/438 |
| DiverticulitisInfections and infestations | 2/435 | 0/438 |
| NephrolithiasisRenal and urinary disorders | 2/435 | 0/438 |
| Acute myocardial infarctionCardiac disorders | 1/435 | 2/438 |
| Angina pectorisCardiac disorders | 1/435 | 2/438 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/435 | 2/438 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/435 | 2/438 |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| NasopharyngitisInfections and infestations | 41/435 | 47/438 |
| Upper respiratory tract infectionInfections and infestations | 45/435 | 34/438 |
| HeadacheNervous system disorders | 36/435 | 22/438 |
| SinusitisInfections and infestations | 11/435 | 23/438 |
Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.
| Age, Continuous(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 58.2 ± 9.9 | 57.2 ± 10.3 | 57.7 ± 10.1 |
| Sex: Female, Male(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Female | 186 | 185 | 371 |
| Male | 253 | 254 | 507 |
| Body Mass Index (BMI)(kilogram per square meter) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 32.8 ± 6.9 | 33.2 ± 6.6 | 33.0 ± 6.7 |
| Duration of Diabetes(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 10.11 ± 6.49 | 9.57 ± 6.22 | 9.84 ± 6.36 |
| Basal Insulin Daily Dose(units per kilogram (U/kg)) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 0.193 ± 0.027 | 0.193 ± 0.034 | 0.193 ± 0.031 |
| Glycated Hemoglobin A1c (HbA1c)(participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Less Than (<) 8% | 141 | 142 | 283 |
| Greater Than or Equal to (>=) 8% | 298 | 297 | 595 |
Showing the first 100 of 217 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Aug 2012, a primary completion of Sep 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 7 months after primary completion. A results delay was requested in Nov 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine